Chromadex Corp
ChromaDex Corporation operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) t… Read more
Chromadex Corp (CDXC) - Net Assets
Latest net assets as of December 2024: $46.09 Million USD
Based on the latest financial reports, Chromadex Corp (CDXC) has net assets worth $46.09 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($66.19 Million) and total liabilities ($20.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $46.09 Million |
| % of Total Assets | 69.64% |
| Annual Growth Rate | 108.02% |
| 5-Year Change | 180.65% |
| 10-Year Change | 773.87% |
| Growth Volatility | 228611.11 |
Chromadex Corp - Net Assets Trend (2007–2024)
This chart illustrates how Chromadex Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chromadex Corp (2007–2024)
The table below shows the annual net assets of Chromadex Corp from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $46.09 Million | +61.98% |
| 2023-12-31 | $28.46 Million | -0.75% |
| 2022-12-31 | $28.67 Million | -9.63% |
| 2021-12-31 | $31.73 Million | +93.17% |
| 2020-12-31 | $16.42 Million | -19.67% |
| 2019-12-31 | $20.45 Million | -24.77% |
| 2018-12-31 | $27.18 Million | -49.51% |
| 2017-12-31 | $53.83 Million | +439.72% |
| 2016-12-31 | $9.97 Million | +89.10% |
| 2015-12-31 | $5.27 Million | +31.92% |
| 2014-12-31 | $4.00 Million | -29.43% |
| 2013-12-31 | $5.67 Million | +41.87% |
| 2012-12-31 | $3.99 Million | +55.91% |
| 2011-12-31 | $2.56 Million | -48.11% |
| 2010-12-31 | $4.94 Million | +371.26% |
| 2009-12-31 | $1.05 Million | -40.12% |
| 2008-12-31 | $1.75 Million | +971657.22% |
| 2007-12-31 | $180.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chromadex Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18187018000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $77.00K | 0.17% |
| Other Comprehensive Income | $-4.00K | -0.01% |
| Other Components | $227.93 Million | 494.49% |
| Total Equity | $46.09 Million | 100.00% |
Chromadex Corp Competitors by Market Cap
The table below lists competitors of Chromadex Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pansoft Company Limited
SHE:300996
|
$400.16 Million |
|
Yan Tai Shuang Ta Food Co Ltd
SHE:002481
|
$400.18 Million |
|
PSG Corp. PCL
BK:PSG
|
$400.54 Million |
|
Sino BiologicalInc.
SHE:301047
|
$400.87 Million |
|
Compass Diversified Holdings
NYSE:CODI
|
$400.10 Million |
|
Major Drilling Group International Inc
PINK:MJDLF
|
$400.06 Million |
|
Nanjing Canatal Data Centre Environmental Tech Co Ltd Class A
SHG:603912
|
$399.97 Million |
|
Columbus McKinnon Corporation
NASDAQ:CMCO
|
$399.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chromadex Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 28,456,000 to 46,094,000, a change of 17,638,000 (62.0%).
- Net income of 8,550,000 contributed positively to equity growth.
- Other factors increased equity by 9,088,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $8.55 Million | +18.55% |
| Other Changes | $9.09 Million | +19.72% |
| Total Change | $- | 61.98% |
Book Value vs Market Value Analysis
This analysis compares Chromadex Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 233746.26x to 13.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.00 | $7.87 | x |
| 2008-12-31 | $0.19 | $7.87 | x |
| 2009-12-31 | $0.11 | $7.87 | x |
| 2010-12-31 | $0.31 | $7.87 | x |
| 2011-12-31 | $0.11 | $7.87 | x |
| 2012-12-31 | $0.12 | $7.87 | x |
| 2013-12-31 | $0.17 | $7.87 | x |
| 2014-12-31 | $0.11 | $7.87 | x |
| 2015-12-31 | $0.15 | $7.87 | x |
| 2016-12-31 | $0.27 | $7.87 | x |
| 2017-12-31 | $1.21 | $7.87 | x |
| 2018-12-31 | $0.49 | $7.87 | x |
| 2019-12-31 | $0.36 | $7.87 | x |
| 2020-12-31 | $0.27 | $7.87 | x |
| 2021-12-31 | $0.47 | $7.87 | x |
| 2022-12-31 | $0.41 | $7.87 | x |
| 2023-12-31 | $0.38 | $7.87 | x |
| 2024-12-31 | $0.59 | $7.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chromadex Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.55%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.88%
- • Asset Turnover: 0.90x
- • Equity Multiplier: 1.48x
- Recent ROE (18.55%) is above the historical average (-1278.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -21323.33% | -0.81% | 8189.66x | 3.22x | $-38.40K |
| 2008 | -120.31% | -46.70% | 1.10x | 2.33x | $-2.28 Million |
| 2009 | -86.65% | -15.71% | 1.62x | 3.40x | $-1.01 Million |
| 2010 | -41.56% | -27.12% | 1.16x | 1.32x | $-2.55 Million |
| 2011 | -308.24% | -97.32% | 1.29x | 2.45x | $-8.15 Million |
| 2012 | -292.05% | -100.45% | 1.29x | 2.26x | $-12.06 Million |
| 2013 | -78.01% | -43.50% | 1.13x | 1.59x | $-4.99 Million |
| 2014 | -134.76% | -35.19% | 1.32x | 2.90x | $-5.79 Million |
| 2015 | -52.54% | -12.59% | 1.17x | 3.55x | $-3.30 Million |
| 2016 | -29.36% | -10.92% | 1.36x | 1.98x | $-3.93 Million |
| 2017 | -21.13% | -53.66% | 0.34x | 1.17x | $-16.76 Million |
| 2018 | -122.58% | -105.57% | 0.75x | 1.55x | $-36.03 Million |
| 2019 | -153.93% | -67.99% | 1.15x | 1.97x | $-33.52 Million |
| 2020 | -112.54% | -31.19% | 1.54x | 2.34x | $-20.13 Million |
| 2021 | -80.55% | -37.89% | 1.17x | 1.82x | $-28.73 Million |
| 2022 | -50.39% | -20.05% | 1.33x | 1.89x | $-17.32 Million |
| 2023 | -17.35% | -5.91% | 1.52x | 1.93x | $-7.78 Million |
| 2024 | 18.55% | 13.88% | 0.90x | 1.48x | $3.94 Million |
Industry Comparison
This section compares Chromadex Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chromadex Corp (CDXC) | $46.09 Million | -21323.33% | 0.44x | $400.11 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |